BPMC Blueprint Medicines Corporation

0  0%
Previous Close 96.77
Price To Book 13.73
Market Cap 4,727,595,096
Shares 48,853,933
Volume 0
Short Ratio
Av. Daily Volume 490,494

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initial data due 2H 2019.
Avapritinib BLU-285 - PIONEER
Indolent and smoldering systemic mastocytosis (SM)
NDA filing announced June 14, 2019.
Avapritinib BLU-285
PDGFRα driven Gastrointestinal stromal tumors (GIST)
Phase 1 China enrolment to commence mid-2019.
Advanced hepatocellular carcinoma (HCC)
Phase 3 trial planned 1H 2018.
Gastrointestinal stromal tumors (GIST) harboring a PDGFRα D842V
Phase 1 updated data at ASCO 2019 - 60% ORR in post-platinum RET-fusion NSCLC and 63% ORR in RET-mutant MTC patients. NDA filing due 1Q 2020.
RET-altered solid tumors
Phase 2 enrolment to be completed 2H 2019. NDA filing due 1Q 2020.
Avapritinib BLU-285 - PATHFINDER
Advanced Systemic mastocytosis (SM)
Phase 1 updated data June 15, 2019 - ORR 77%. NDA filing due 1Q 2020.
Avapritinib BLU-285 - EXPLORER
Advanced Systemic mastocytosis (SM)
Phase 3 enrolment to be completed 2H 2019.
Avapritinib - Voyager
Gastrointestinal stromal tumors (GIST)
Phase 1 trial initiated 1Q 2019.
Fibrodysplasia ossificans progressiva (FOP)

Latest News

  1. Blueprint Medicines Presents Updated EXPLORER Trial Data for Avapritinib in Patients with Systemic Mastocytosis at 24th EHA Congress
  2. Edited Transcript of BPMC earnings conference call or presentation 9-May-19 12:30pm GMT
  3. Blueprint Medicines Submits New Drug Application to U.S. Food and Drug Administration for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
  4. See what the IHS Markit Score report has to say about Blueprint Medicines Corp.
  5. Who Are The Winners And Losers From The Year's Biggest Cancer Meeting?
  6. Blueprint Medicines' NDA for Avapritinib on Track for GIST
  7. Blueprint Medicines' Highly Selective RET Inhibitor BLU-667 Shows Durable Anti-Tumor Activity in Patients with RET-Altered Cancers in Updated ARROW Trial Data Presented at ASCO 2019
  8. Blueprint Medicines Presents NAVIGATOR Trial Data in PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST at ASCO 2019 Supporting Planned Marketing Applications for Avapritinib
  9. Blueprint Medicines to Present at Upcoming Investor Conferences in June
  10. 2 Top Stocks to Watch at ASCO 2019
  11. Blueprint Medicines Announces Data Presentations at ASCO and EHA Meetings from Registration-Enabling Clinical Trials of Avapritinib and BLU-667 Across Multiple Patient Populations
  12. 3 Stocks With Big News Coming at ASCO 2019
  13. How Much is Blueprint Medicines Corporation's (NASDAQ:BPMC) CEO Getting Paid?
  14. Blueprint Medicines (BPMC) Q1 Earnings & Sales Lag Estimates
  15. Blueprint Medicines (BPMC) Q1 2019 Earnings Call Transcript
  16. Blueprint Medicines (BPMC) Reports Q1 Loss, Misses Revenue Estimates
  17. Blueprint Medicines: 1Q Earnings Snapshot
  18. Blueprint Medicines Reports First Quarter 2019 Financial Results
  19. Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More
  20. Blueprint Medicines to Present at Bank of America Merrill Lynch 2019 Health Care Conference